ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed ...

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results ...

Sanofi’s Dupixent has been granted FDA priority review for the treatment of bullous pemphigoid (BP), a chronic skin disease. If approved, Dupix ...

Filing of the 2024 U.S. Form 20-F and French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its ...

The Department of Health and Human Services’ newly hired tech officers’ futures are in limbo as the Trump administration ...

A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi and Johnson & Johnson’s ...

Hanau-native Julian Chabot’s path to top flight football in his native country proved an unconventional one. It was only after several years playing outside of Germany that the Stuttgart defender ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, ...